This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Thursday's Health Winners & Losers

Preliminary second-quarter revenue and patent cops-and-robbers sent SonoSite (SONO) up on an otherwise ho-hum day for biotech stocks.

SonoSite, a handheld ultrasound device maker, climbed after reporting strong preliminary results for the quarter ended June 30. The company said that due to improved sales, quarterly revenue grew about 20% to more than $47 million compared to the same quarter in 2006.

For the first half of the fiscal year, SonoSite said worldwide revenue grew about 18% to some $90 million compared with $76.4 million for the first half of the previous year.

The company also said Thursday that it's filing a counterclaim against General Electric (GE) and certain of its affiliates to the complaint those parties filed against it on May 15. SonoSite said it's filing its answer to the complaint denying all of GE's claims and alleging that the asserted patents are either invalid, not infringed or both.

SonoSite alleges in the counterclaim complaint that GE and its affiliated companies infringed on its patents for two diagnostic instruments. SonoSite scaled $3.40, or 10.5%, to $36.45, while GE lost 10 cents, or 0.5%, to $38.51.

Also on the move, Cell Therapeutics (CTIC) climbed 44 cents, or 14.6%, to $3.46.

The company said Tuesday after market close, that it named a new medical director for its XYOTAX/CT-2103 program, which involves a candidate for ovarian cancer and lung cancer in women. Dr. Jay Umbreit will take over the company's PGT307 trial. Umbreit most recently developed pharmaceutical products for PPD, a global contract research organization.

Cell Therapeutics is part of the Nasdaq Biotechnology Index, which was down 1.35, or 0.2%, to 810.89.

RadNet (RDNT) was also up after the company announced that it had established a $445 million credit line with GE Healthcare Financial Services to refinance existing debt and also to fund working capital for future expansion.

The diagnostic imaging services company said it expects annual interest cost savings of about $5.4 million and believes the financing will be completed by August 2007. RadNet was up 20 cents, or 2.04%, to $10.

Elsewhere, Advanced Medical Optics (EYE) made a $75-a-share bid for Bausch & Lomb (BOL), according to a report in The Wall Street Journal citing people familiar with the matter. The bid would compete with Warburg Pincus' offer, valued at $45 in cash and $30 in stock.

Advanced Medical Optics rose 42 cents, or 1.2%, to $35.89, while Bausch & Lomb jumped $3.36, or 4.9%, to $72.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,390.52 +195.10 1.13%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,630.7410 +64.6030 1.41%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs